Novo Nordisk Raises Forecasts on New Obesity Drug

Aug. 05-- Lars Fruergaard Jorgensen, Novo Nordisk primary executive policeman, discusses very first fifty percent earnings results. The Danish drug-maker elevated its earnings as well as sales projections for the year, reflecting high demand for its new obesity medication. He consults with Bloomberg's Dani Burger on "Bloomberg Surveillance: Early Edition".

Leave a Reply

Your email address will not be published. Required fields are marked *